The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
Raul Cordoba, MD, PhD, Fundación Jiménez Díaz, Madrid, Spain, emphasizes the importance of preventing and monitoring cardiotoxicities in patients with hematologic malignancies. In 2022, the European Society of Cardiology (ESC) and the European Hematology Association (EHA) issued new guidelines recommending specific tests before, during, and after treatment to manage and detect both immediate and late-term cardiotoxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
